$642 Million is the total value of Octagon Capital Advisors LP's 32 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 60.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $163,403,600 | -4.4% | 3,160,000 | +26.2% | 25.44% | -13.8% |
| KDNY | CHINOOK THERAPEUTICS INC | $66,854,619 | +33.3% | 2,551,703 | 0.0% | 10.41% | +20.2% | |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $64,488,840 | +376.3% | 2,468,000 | +86.3% | 10.04% | +329.7% |
| RCUS | Sell | ARCUS BIOSCIENCES INC | $51,342,236 | -26.4% | 2,482,700 | -7.0% | 7.99% | -33.6% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $33,982,500 | +120.2% | 750,000 | +239.4% | 5.29% | +98.6% |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $33,935,509 | +58.6% | 761,398 | 0.0% | 5.28% | +43.0% | |
| ISEE | New | IVERIC BIO INC | $27,361,980 | – | 1,278,000 | +100.0% | 4.26% | – |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $24,074,882 | – | 824,200 | +100.0% | 3.75% | – |
| TNDM | TANDEM DIABETES CARE INC | $21,348,059 | -6.1% | 474,929 | 0.0% | 3.32% | -15.2% | |
| AVTE | New | AEROVATE THERAPEUTICS INC | $18,216,162 | – | 621,712 | +100.0% | 2.84% | – |
| XBI | Sell | SPDR SER TRs&p biotech | $16,551,611 | -14.3% | 199,417 | -18.1% | 2.58% | -22.7% |
| VERA | Buy | VERA THERAPEUTICS INCcl a | $12,870,769 | +13.3% | 665,156 | +24.7% | 2.00% | +2.2% |
| ITCI | INTRA-CELLULAR THERAPIES INC | $11,692,833 | +13.7% | 220,953 | 0.0% | 1.82% | +2.6% | |
| CBAY | New | CYMABAY THERAPEUTICS INC | $11,657,184 | – | 1,859,200 | +100.0% | 1.82% | – |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $11,104,911 | +176.2% | 499,996 | 0.0% | 1.73% | +149.1% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $9,003,750 | +2.1% | 1,225,000 | 0.0% | 1.40% | -7.9% | |
| ITOS | New | ITEOS THERAPEUTICS INC | $8,690,850 | – | 445,000 | +100.0% | 1.35% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $8,182,700 | – | 870,500 | +100.0% | 1.27% | – |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $7,203,518 | +16.2% | 324,629 | -14.5% | 1.12% | +4.9% |
| BBIO | BRIDGEBIO PHARMA INC | $7,115,122 | -23.3% | 933,743 | 0.0% | 1.11% | -30.8% | |
| STOK | STOKE THERAPEUTICS INC | $7,046,699 | -28.1% | 763,456 | 0.0% | 1.10% | -35.2% | |
| XILIO THERAPEUTICS INC | $6,523,250 | -7.6% | 2,425,000 | 0.0% | 1.02% | -16.6% | ||
| ETNB | New | 89BIO INC | $4,837,400 | – | 380,000 | +100.0% | 0.75% | – |
| GOSS | Sell | GOSSAMER BIO INC | $4,249,010 | -82.7% | 1,958,069 | -4.3% | 0.66% | -84.3% |
| MIRM | MIRUM PHARMACEUTICALS INC | $1,950,000 | -7.2% | 100,000 | 0.0% | 0.30% | -16.3% | |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $1,904,000 | – | 800,000 | +100.0% | 0.30% | – |
| DXCM | Sell | DEXCOM INC | $1,698,600 | -47.3% | 15,000 | -62.5% | 0.26% | -52.5% |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $1,650,000 | – | 15,000 | +100.0% | 0.26% | – |
| JNCE | JOUNCE THERAPEUTICS INC | $1,554,000 | -52.6% | 1,400,000 | 0.0% | 0.24% | -57.2% | |
| MREO | MEREO BIOPHARMA GROUP PLCspon ads | $750,000 | -12.9% | 1,000,000 | 0.0% | 0.12% | -21.5% | |
| Sell | NUVALENT INC | $744,500 | -80.9% | 25,000 | -87.5% | 0.12% | -82.7% | |
| IPSC | Sell | CENTURY THERAPEUTICS INC | $230,850 | -89.6% | 45,000 | -79.9% | 0.04% | -90.6% |
| ADCT | Exit | ADC THERAPEUTICS SA | $0 | – | -30,000 | -100.0% | -0.02% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -20,000 | -100.0% | -0.08% | – |
| CNTB | Exit | CONNECT BIOPHARMA HLDGS LTDads | $0 | – | -450,000 | -100.0% | -0.10% | – |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -11,300 | -100.0% | -0.26% | – |
| AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -75,000 | -100.0% | -0.44% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -579,061 | -100.0% | -0.56% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -331,096 | -100.0% | -1.28% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -37,300 | -100.0% | -1.29% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -34,500 | -100.0% | -1.34% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -83,500 | -100.0% | -1.49% | – |
| HRMY | Exit | HARMONY BIOSCIENCES HLDGS IN | $0 | – | -243,500 | -100.0% | -1.86% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -624,500 | -100.0% | -6.67% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.